356 related articles for article (PubMed ID: 29515029)
1. Fine epitope signature of antibody neutralization breadth at the HIV-1 envelope CD4-binding site.
Cheng HD; Grimm SK; Gilman MS; Gwom LC; Sok D; Sundling C; Donofrio G; Karlsson Hedestam GB; Bonsignori M; Haynes BF; Lahey TP; Maro I; von Reyn CF; Gorny MK; Zolla-Pazner S; Walker BD; Alter G; Burton DR; Robb ML; Krebs SJ; Seaman MS; Bailey-Kellogg C; Ackerman ME
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515029
[TBL] [Abstract][Full Text] [Related]
2. HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
Ditse Z; Muenchhoff M; Adland E; Jooste P; Goulder P; Moore PL; Morris L
J Virol; 2018 Sep; 92(17):. PubMed ID: 29950423
[TBL] [Abstract][Full Text] [Related]
3. Near-Pan-neutralizing, Plasma Deconvoluted Antibody N49P6 Mimics Host Receptor CD4 in Its Quaternary Interactions with the HIV-1 Envelope Trimer.
Tolbert WD; Nguyen DN; Tehrani ZR; Sajadi MM; Pazgier M
mBio; 2021 Aug; 12(4):e0127421. PubMed ID: 34281393
[TBL] [Abstract][Full Text] [Related]
4. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
[TBL] [Abstract][Full Text] [Related]
5. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
[TBL] [Abstract][Full Text] [Related]
6. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 gp120-CD4-Induced Antibody Complex Elicits CD4 Binding Site-Specific Antibody Response in Mice.
Galkin A; Chen Y; Guenaga J; O'Dell S; Acevedo R; Steinhardt JJ; Wang Y; Wilson R; Chiang CI; Doria-Rose N; Grishaev AV; Mascola JR; Li Y
J Immunol; 2020 Mar; 204(6):1543-1561. PubMed ID: 32066595
[TBL] [Abstract][Full Text] [Related]
8. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
9. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
Front Immunol; 2021; 12():670561. PubMed ID: 35003053
[TBL] [Abstract][Full Text] [Related]
10. Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method.
Evans MC; Phung P; Paquet AC; Parikh A; Petropoulos CJ; Wrin T; Haddad M
BMC Bioinformatics; 2014 Mar; 15():77. PubMed ID: 24646213
[TBL] [Abstract][Full Text] [Related]
11. Increased Epitope Complexity Correlated with Antibody Affinity Maturation and a Novel Binding Mode Revealed by Structures of Rabbit Antibodies against the Third Variable Loop (V3) of HIV-1 gp120.
Pan R; Qin Y; Banasik M; Lees W; Shepherd AJ; Cho MW; Kong XP
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343576
[TBL] [Abstract][Full Text] [Related]
12. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
13. Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
Wu X; Wang C; O'Dell S; Li Y; Keele BF; Yang Z; Imamichi H; Doria-Rose N; Hoxie JA; Connors M; Shaw GM; Wyatt RT; Mascola JR
J Virol; 2012 May; 86(10):5844-56. PubMed ID: 22419808
[TBL] [Abstract][Full Text] [Related]
14. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
15. Impact of amino acid substitutions in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site.
Utachee P; Isarangkura-na-ayuthaya P; Tokunaga K; Ikuta K; Takeda N; Kameoka M
Retrovirology; 2014 Apr; 11():32. PubMed ID: 24758333
[TBL] [Abstract][Full Text] [Related]
16. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins.
Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT
J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963
[TBL] [Abstract][Full Text] [Related]
17. High-resolution definition of vaccine-elicited B cell responses against the HIV primary receptor binding site.
Sundling C; Li Y; Huynh N; Poulsen C; Wilson R; O'Dell S; Feng Y; Mascola JR; Wyatt RT; Karlsson Hedestam GB
Sci Transl Med; 2012 Jul; 4(142):142ra96. PubMed ID: 22786681
[TBL] [Abstract][Full Text] [Related]
18. Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.
Khan L; Kumar R; Thiruvengadam R; Parray HA; Makhdoomi MA; Kumar S; Aggarwal H; Mohata M; Hussain AW; Das R; Varadarajan R; Bhattacharya J; Vajpayee M; Murugavel KG; Solomon S; Sinha S; Luthra K
Sci Rep; 2017 Mar; 7():45163. PubMed ID: 28332627
[TBL] [Abstract][Full Text] [Related]
19. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
20. New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional Potency.
Doria-Rose NA; Bhiman JN; Roark RS; Schramm CA; Gorman J; Chuang GY; Pancera M; Cale EM; Ernandes MJ; Louder MK; Asokan M; Bailer RT; Druz A; Fraschilla IR; Garrett NJ; Jarosinski M; Lynch RM; McKee K; O'Dell S; Pegu A; Schmidt SD; Staupe RP; Sutton MS; Wang K; Wibmer CK; Haynes BF; Abdool-Karim S; Shapiro L; Kwong PD; Moore PL; Morris L; Mascola JR
J Virol; 2016 Jan; 90(1):76-91. PubMed ID: 26468542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]